A Phase 4 interventional study of Tadalafil 5mg and estradiol valerate 2 mg in IVF and Infertility, Female, sponsored by Beni-Suef University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Beni-Suef University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Infertility, Female with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Infertility, Female · Egypt.
Among the 60 studies in Infertility, Female with a site in Egypt, this one is the 33rd largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2023, is one of 15 in phase 4, and was the 59th registered.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
Browse Infertility, Female studies →6 of the 60 studies in Infertility, Female with a site in Egypt are open now. Recruiting first, the newest first:
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy · Sites in Egypt
Ages 20–40 · Women only
Assiut University · Sites in Egypt
Ages 18–40 · Women only
Assiut University · Sites in Egypt
Ages 18–35 · Women only
Zagazig University · Sites in Egypt
Ages 21–40 · Women only · Healthy volunteers
Sohag University · Sites in Egypt
Ages 18–40 · Women only
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 43 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 6 · Phase 4 15
First in 2013; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 141 across the 46 interventional studies, 163 across the 14 observational. Of the 32 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 60 have an industry lead sponsor. The 10 most frequent:
Beni-Suef University is the lead sponsor of 350 studies on the registry; 124 are open to participants now.
Beni-Suef University has 4 studies filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 60 studies in Infertility, Female with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
investigate the effect of different vasodilators as Tadalafil in women with unexplained infertility using IVF
This prospective randomized clinical study was carried out on 100 women, aged \<18 to 43 years old, has good quality day five frozen embryos. The study was done after approval from the Ethical Committee Beni Suef University Hospitals, Beni Suef, Egypt. An informed written consent was obtained from the patients.
Randomization and blindness:
An online randomization program (http://www.randomizer.org ) was used to generate a random list and each patient's code was kept in an opaque sealed envelope. Patients were randomly allocated with 1:1 allocation ratio into two equal groups in a parallel manner: Group 1 (control): Patients received estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) white pills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial thickness in day 9 measured by vaginal ultrasound.
Group 2: received tadalafil 5 mg. once daily in form of (tadanerfi 5® Nerhadou international5 co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone. All patients were subjected to complete history taking, general examination, laboratory investigations [Anti-müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E₂), prolactin (PRL) and thyroid-stimulating hormone (TSH)] and radiological investigations [Ultrasonography].
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients received estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) white pills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial thickness in day 9 measured by vaginal ultrasound.
Drug: estradiol valerate 2 mg
once daily in form of (tadanerfi 5® Nerhadou international5 co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone
Drug: Tadalafil 5mg
phosphodiesterase type 5 (PDE-5) inhibitor
estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) white pills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial thickness in day 9 measured by vaginal ultrasound.
Also known as: Cycloprogynova®
pregnancy
whom Beta-Human Chorionic Gonadotropin (β-hCG) was positive
Time frame: 1 month
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Apr 2026, 30 months after the start.
Of 32 non-industry phase 4 interventional studies under Infertility, Female, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 30 months is above that.
Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 14 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil